Founded in 2014, Tonghua Anrate Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise focusing on the research and development of recombinant human albumin, with a total investment of 1.117 billion yuan and more than 500 employees. After years of hard research and development, Anrate has explored a mature recombinant human albumin manufacturing process, and has a number of world-leading patents such as methanol-free Pichia pastoris protein green production technology, overcoming technical problems such as recombinant protein impurity analysis and immunogenicity control, achieving a significant reduction in production costs, and breaking the risk of virus transmission in blood products through technological innovation. At present, Anrate has successfully obtained the approval of the Eurasian Economic Union-Ministry of Health of the Russian Federation for marketing in April 2024, becoming the world's first and only marketed recombinant human albumin injection product. Today, relying on the advantages of large tonnage production capacity, Anrate expands its product pipeline, continues to promote the development of the biopharmaceutical field, and is committed to providing professional solutions for the global health cause.

通化安睿特生物制藥股份有限公司成立于2014年，是專注重組人白蛋白研發(fā)的高科技生物制藥企業(yè)，總投資11.17億元，員工500余人。經多年努力研發(fā)，安睿特探索出成熟的重組人白蛋白生產工藝，并擁有無甲醇畢赤酵母蛋白質綠色生產技術等多項專利，攻克重組蛋白雜質分析、免疫原性控制等技術難題，實現(xiàn)生產成本大幅降低，通過技術創(chuàng)新打破血源病毒傳播風險。目前安睿特已于2024年4月成功獲得歐亞經濟聯(lián)盟﹣俄羅斯聯(lián)邦衛(wèi)生部批準上市，成為全球首個，也是唯一一個上市的重組人白蛋白注射液產品。如今，安睿特依托大噸位產能優(yōu)勢拓展產品管線，持續(xù)推動生物制藥領域發(fā)展，致力于為全球健康事業(yè)提供專業(yè)解決方案。